Nothing Special   »   [go: up one dir, main page]

EA200970486A1 - Соединения для ингибирования митоза - Google Patents

Соединения для ингибирования митоза

Info

Publication number
EA200970486A1
EA200970486A1 EA200970486A EA200970486A EA200970486A1 EA 200970486 A1 EA200970486 A1 EA 200970486A1 EA 200970486 A EA200970486 A EA 200970486A EA 200970486 A EA200970486 A EA 200970486A EA 200970486 A1 EA200970486 A1 EA 200970486A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
mytoze
inhibition
methods
present
Prior art date
Application number
EA200970486A
Other languages
English (en)
Other versions
EA015779B1 (ru
Inventor
Кристофер Ф. Клэйборн
Тодд Б. Селлс
Стефен Г. Страуд
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA200970486A1 publication Critical patent/EA200970486A1/ru
Publication of EA015779B1 publication Critical patent/EA015779B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I) и к способам лечения рака. В частности, настоящее изобретение предусматривает активные ингибиторы Aurora А киназы, фармацевтические композиции, содержащие эти соединения, и способы применения соединений для лечения рака.
EA200970486A 2006-11-16 2007-11-14 Соединения для ингибирования митоза EA015779B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (2)

Publication Number Publication Date
EA200970486A1 true EA200970486A1 (ru) 2009-10-30
EA015779B1 EA015779B1 (ru) 2011-12-30

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970486A EA015779B1 (ru) 2006-11-16 2007-11-14 Соединения для ингибирования митоза

Country Status (35)

Country Link
US (6) US8026246B2 (ru)
EP (4) EP2944639B1 (ru)
JP (3) JP5102839B2 (ru)
KR (2) KR101110458B1 (ru)
CN (2) CN101547924B (ru)
AR (1) AR064246A1 (ru)
AT (1) ATE556076T1 (ru)
AU (1) AU2007322046B2 (ru)
BR (1) BRPI0718803B8 (ru)
CA (1) CA2669680C (ru)
CL (1) CL2007003244A1 (ru)
CR (3) CR10782A (ru)
CY (1) CY1112828T1 (ru)
DK (2) DK2086981T3 (ru)
EA (1) EA015779B1 (ru)
ES (3) ES2537451T3 (ru)
GE (1) GEP20125459B (ru)
HK (4) HK1134672A1 (ru)
HR (2) HRP20120490T1 (ru)
IL (1) IL198690A0 (ru)
MA (1) MA30988B1 (ru)
MX (3) MX348568B (ru)
MY (1) MY153243A (ru)
NO (1) NO343338B1 (ru)
NZ (3) NZ611898A (ru)
PH (1) PH12012502057B1 (ru)
PL (2) PL2086981T3 (ru)
PT (2) PT2497772E (ru)
RS (2) RS53788B1 (ru)
SG (2) SG176443A1 (ru)
SI (2) SI2086981T1 (ru)
TW (1) TWI401255B (ru)
UA (1) UA94129C2 (ru)
WO (1) WO2008063525A1 (ru)
ZA (1) ZA200903279B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JP5684719B2 (ja) * 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
KR101741168B1 (ko) * 2008-12-22 2017-05-29 밀레니엄 파머슈티컬스 인코퍼레이티드 오로라 키나아제 억제제 및 항­ｃｄ 항체의 병용
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
UY34114A (es) * 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
US20180263979A1 (en) * 2014-12-23 2018-09-20 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
IL59316A (en) 1979-02-07 1983-07-31 Sparamedica Ag Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU723860B2 (en) 1996-03-08 2000-09-07 Astrazeneca Ab Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
TW510902B (en) 1997-09-29 2002-11-21 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE403644T1 (de) 1999-12-06 2008-08-15 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
EP2264028A1 (en) 2000-12-21 2010-12-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
AU2002328999B8 (en) 2001-08-09 2008-06-05 Actelion Pharmaceuticals Ltd. Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005111039A2 (en) 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
AU2006330587B2 (en) 2005-12-23 2012-12-13 Glaxosmithkline Llc Azaindole inhibitors of aurora kinases
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EP2944639B1 (en) 2017-01-04
EP2497772B1 (en) 2014-10-29
DK2086981T3 (da) 2012-08-06
CN101547924B (zh) 2013-09-25
HRP20150047T1 (en) 2015-03-13
NZ577042A (en) 2012-03-30
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
JP2012006965A (ja) 2012-01-12
KR20090091173A (ko) 2009-08-26
SI2086981T1 (sl) 2012-12-31
NZ597252A (en) 2013-06-28
ES2537451T3 (es) 2015-06-08
AU2007322046B2 (en) 2012-04-05
US20110312943A1 (en) 2011-12-22
EA015779B1 (ru) 2011-12-30
US20080167292A1 (en) 2008-07-10
TW200829589A (en) 2008-07-16
EP2497773B1 (en) 2015-02-25
CR20140544A (es) 2015-01-12
US8026246B2 (en) 2011-09-27
GEP20125459B (en) 2012-03-26
HK1175777A1 (en) 2013-07-12
UA94129C2 (ru) 2011-04-11
JP5102839B2 (ja) 2012-12-19
CA2669680A1 (en) 2008-05-29
EP2086981B1 (en) 2012-05-02
CA2669680C (en) 2012-04-10
IL198690A0 (en) 2010-02-17
US20150166545A1 (en) 2015-06-18
KR101342014B1 (ko) 2013-12-19
SG10201503350TA (en) 2015-06-29
TWI401255B (zh) 2013-07-11
PT2497772E (pt) 2015-02-05
ATE556076T1 (de) 2012-05-15
RS52313B (en) 2012-12-31
US9988384B2 (en) 2018-06-05
SI2497772T1 (sl) 2015-03-31
US20210214361A1 (en) 2021-07-15
CN103483343B (zh) 2016-06-01
US11958855B2 (en) 2024-04-16
AR064246A1 (es) 2009-03-25
EP2497773A1 (en) 2012-09-12
MA30988B1 (fr) 2009-12-01
MX348568B (es) 2017-06-20
ZA200903279B (en) 2010-07-28
NO343338B1 (no) 2019-02-04
AU2007322046A1 (en) 2008-05-29
ES2384123T3 (es) 2012-06-29
PH12012502057A1 (en) 2015-09-14
KR20110113210A (ko) 2011-10-14
CL2007003244A1 (es) 2008-04-04
US9765076B2 (en) 2017-09-19
HK1175778A1 (en) 2013-07-12
BRPI0718803B8 (pt) 2021-05-25
ES2528793T3 (es) 2015-02-12
PL2497772T3 (pl) 2015-05-29
JP2014055166A (ja) 2014-03-27
CR20140154A (es) 2014-07-23
CN101547924A (zh) 2009-09-30
JP2010510215A (ja) 2010-04-02
KR101110458B1 (ko) 2012-03-13
DK2497772T3 (en) 2015-01-19
US10836766B2 (en) 2020-11-17
PL2086981T3 (pl) 2012-09-28
BRPI0718803B1 (pt) 2020-11-17
US20190031662A1 (en) 2019-01-31
NO20091864L (no) 2009-06-15
US20110312942A1 (en) 2011-12-22
HRP20120490T1 (hr) 2012-07-31
JP5452811B2 (ja) 2014-03-26
NZ611898A (en) 2015-01-30
HK1134672A1 (en) 2010-05-07
HK1217699A1 (zh) 2017-01-20
PH12012502057B1 (en) 2015-09-14
CR10782A (es) 2009-06-24
MY153243A (en) 2015-01-29
RS53788B1 (en) 2015-06-30
SG176443A1 (en) 2011-12-29
EP2086981A1 (en) 2009-08-12
CN103483343A (zh) 2014-01-01
BRPI0718803A2 (pt) 2013-12-03
EP2497772A1 (en) 2012-09-12
EP2944639A1 (en) 2015-11-18
WO2008063525A1 (en) 2008-05-29
CY1112828T1 (el) 2016-02-10
MX343391B (es) 2016-11-04

Similar Documents

Publication Publication Date Title
EA200970486A1 (ru) Соединения для ингибирования митоза
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA200970156A1 (ru) Пиридизиноновые производные
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
EA200970680A1 (ru) N-замещенные производные глицина: ингибиторы гидроксилаз
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
EA201400111A1 (ru) Ингибиторы mek и способы их применения
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
EA200801137A1 (ru) Соединения для ингибирования апоптоза
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
EA200970361A1 (ru) Ингибиторы киназы